- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04133714
A Multi-center RCT Study on the Efficacy and Mechanism of Multi-channel tDCS in Rehabilitation of Cognitive Function After Stroke
This clinical RCT study intends to combined different forms of multi-channel tDCS with the routine cognitive training process to treat patients with post-stroke cognitive dysfunction.
The therapeutic effects among single-channel tDCS group, multi-channel tDCS and pseudo-multichannel tDCS group will be compared. Brain magnetic resonance mechanism research will also be included to reveal the possible mechanism of multi-channel tDCS technology for PSCI brain network.
Thus, the efficacy and mechanism of multi-channel tDCS in post-stroke cognitive function rehabilitation will be researched both in the clinical and basic levels.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Hongjie Jiang, Dr.
- Telefonnummer: +86 13777830137
- E-Mail: insjhj@zju.edu.cn
Studienorte
-
-
-
Chongqing, China, 400000
- Rekrutierung
- Southwest Hospital
-
Kontakt:
- Jingming Hou, Dr.
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310014
- Rekrutierung
- Zhejiang Provincial People's Hospital
-
Kontakt:
- Ruidong Cheng, Dr.
-
Hangzhou, Zhejiang, China, 310009
- Rekrutierung
- SAHZhejiangU
-
Kontakt:
- Hongjie Jiang, Dr.
-
Hangzhou, Zhejiang, China, 310000
- Rekrutierung
- Rainbowfish Rehabilitation Nursing Care
-
Kontakt:
- Ran Wang, Dr.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 18-60 year-old
- diagnosed cerebral apoplexy, meeting the diagnostic criteria of ICD-10
- cognitive function, perceptual function decline after stroke
- first onset and duration of 3-12 months
- right-handed
- MMSE ≤25
- MoCA ≤25
- sign informed consent voluntarily and comply with the study plan
Exclusion Criteria:
- NIHSS ≥21 points
- MoCA ≤18, or DRS-2 ≤ 124, or CES-D ≥ 16
- taking drugs that affect central nervous activity, such as nerve antagonists
- specific contraindication, such as electrode patch allergy, local skin injury or - - - - inflammation, and hyperalgesia in stimulated areas
- patients use implantable electronic devices (such as cardiac pacemakers) or have - metal implants such as stents that affect MRI examination
- patients with a previous history of epilepsy, mental illness or skull injury
- patients with dementia or obvious cognitive dysfunction before stroke
- patients with aphasia or dysarthria and cannot complete the scale evaluation
- pregnancy
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: multi-channel tDCS
In the multi-channel tDCS stimulation group, a 1:4 (anode: cathode) approach was applied, with the central anode placed in the left dorsolateral prefrontal cortex (dlPFC) (reference 10-20 standard lead EEG), and the remaining cathode distributed around the central electrode. The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off). |
multi-channel transcranial direct current stimulation, tDCS
|
|
Experimental: single-channel tDCS
The anode electrode of the single-channel tDCS stimulation group was placed in the left dlPFC, and the cathode electrode was placed in the right orbital forehead. The rising time and falling time of current are 30 seconds respectively. Stimulate 30 minutes daily for 10 days (Monday to Friday, once a day, weekend off). |
single-channel transcranial direct current stimulation
|
|
Schein-Komparator: sham stimulation
The shame stimulation group had only 30 seconds of up and down stimulation, with no intermediate stimulation.
|
multi-channel transcranial direct current stimulation, tDCS
single-channel transcranial direct current stimulation
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
MMSE
Zeitfenster: Change from Baseline MMSE at 2 weeks and 3 months after intervention
|
Mini-mental State Examination
|
Change from Baseline MMSE at 2 weeks and 3 months after intervention
|
|
MoCA
Zeitfenster: Change from Baseline MoCA at 2 weeks and 3 months after intervention
|
Montreal Cognitive Assessment
|
Change from Baseline MoCA at 2 weeks and 3 months after intervention
|
|
AVLT
Zeitfenster: Change from Baseline AVLT at 2 weeks and 3 months after intervention
|
The Auditory-Verbal Learning Test
|
Change from Baseline AVLT at 2 weeks and 3 months after intervention
|
|
WAIS-DST
Zeitfenster: Change from Baseline WAIS-DST at 2 weeks and 3 months after intervention
|
WAIS Digit Symbol Test
|
Change from Baseline WAIS-DST at 2 weeks and 3 months after intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
DEX
Zeitfenster: Change from Baseline DEX at 2 weeks and 3 months after intervention
|
Dysexecutive Ques-tionnaire
|
Change from Baseline DEX at 2 weeks and 3 months after intervention
|
|
GNAT
Zeitfenster: Change from Baseline GNAT at 2 weeks and 3 months after intervention
|
Go/No-go Association Task
|
Change from Baseline GNAT at 2 weeks and 3 months after intervention
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Hongjie Jiang, Dr., Second Affiliated Hospital, School of Medicine, Zhejiang University
- Hauptermittler: Ruidong Cheng, Dr., Zhejiang Provincial People's Hospital
- Hauptermittler: Rang Wang, Dr., Rainbowfish Rehabilitation Nursing Care
- Hauptermittler: Jingming Hou, Dr., Southwest Hospital, China
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Voraussichtlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2019-313
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .